©The Author(s) 2026.
World J Diabetes. Feb 15, 2026; 17(2): 111453
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.111453
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.111453
Figure 1 Jiangtang Tiaozhi formula attenuated glycolipid metabolic disorder in vivo.
A: Fasting glucose of mice during treatment (n = 8); B: Oral glucose tolerance test (OGTT) (n = 8); C: Body weight (n = 8); D: Triglyceride (n = 8); E: Total cholesterol (n = 8); F: Fasting glucose of mice after 8 weeks of treatment (n = 8); G: Area under the curve of OGTT (n = 8). aP < 0.05. bP < 0.01. cP < 0.001. NS: Not significant; JTTZF: Jiangtang Tiaozhi formula; OGTT: Oral glucose tolerance test; TG: Triglyceride; TC: Total cholesterol; AUC: Area under the curve.
- Citation: Tian JX, Zhang YJ, Zhang YX, Wei JH, Fang XY, Miao RY, Ma KL, Guan HF, Wang XM, Wu HR. Integrated hepatic transcriptome and metabolome reveal the mechanisms of Jiangtang Tiaozhi formula on improving glycolipid metabolic disorder. World J Diabetes 2026; 17(2): 111453
- URL: https://www.wjgnet.com/1948-9358/full/v17/i2/111453.htm
- DOI: https://dx.doi.org/10.4239/wjd.v17.i2.111453